Table 3 Treatments and outcomes of COVID-19 patients
Total (n = 252) | Non-critically ill (n = 200) | Critically ill (n = 52) | p value | |
|---|---|---|---|---|
Treatments | ||||
Antiviral treatment | 250 (99.20) | 200 (100.00) | 50 (96.20) | 0.042 |
Antibiotics | 202 (80.20) | 155 (77.50) | 47 (90.40) | 0.038 |
Corticosteroids | 28 (11.10) | 15 (7.50) | 13 (25.00) | 0.0003 |
Intravenous immunoglobin | 11 (4.40) | 1 (0.50) | 10 (19.20) | < 0.0001 |
Albumin | 7 (2.80) | 0 | 7 (13.50) | < 0.0001 |
Traditional Chinese medicine | 192 (76.20) | 160 (80.00) | 32 (61.50) | 0.005 |
Oxygen therapy | 200 (79.40) | 158 (79.00) | 42 (80.80) | 0.779 |
Mechanical ventilation | 10 (4.00) | 0 | 10 (19.20) | < 0.0001 |
ECMO | 4 (1.60) | 0 | 4 (7.70) | 0.002 |
Outcomes | ||||
ARDS | 21 (8.40) | 1 (0.50) | 20 (38.50) | < 0.0001 |
ICU admission | 43 (17.10) | 0 | 43 (82.70) | < 0.0001 |
Death | 6 (2.40) | 0 | 6 (11.50) | < 0.0001 |
Time from illness onset to dyspnea, days | 6 (2.75–9.25) | 5.00 (1.50–7.50) | 7 (3–10) | 0.294 |
Time from illness onset to ARDS, days | 9 (6.50–13.50) | 2 | 9.50 (7–13.75) | 0.137 |
Time from illness onset to ICU admission, days | 10 (6–18) | / | 10 (6–18) | |
length of hospital stay | 17 (14–20) | 17 (14–19) | 21.50 (17–27.75) | 0.001 |
Time from hospitalization to death | 8.50 (4–12) | / | 10 (6–18) | |